Submitted by Anonymous (not verified) on 9 November 2023 - 14:42
Opinion/decision on a Paediatric investigation plan (PIP): Human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor on activated T cells (rocatinlimab), decision type: , therapeutic area: , PIP number: P/0017/2023
Source: